Form 4: Vigil Neuroscience Director Bruce Booth Receives Stock Option Grant

Director Bruce Booth receives a stock option grant from Vigil Neuroscience in lieu of cash compensation.

Summary

• Bruce Booth, a director at Vigil Neuroscience, received a stock option grant on March 1, 2024.
• The grant is for 34,612 shares of common stock with an exercise price of $3.39.
• The option was awarded in lieu of cash compensation under the Issuer's Non-Employee Director Compensation Policy.
• The options vest in four equal quarterly installments, starting March 31, 2024.
• Booth is a member of Atlas Venture Associates XII, LLC and will transfer any economic benefit from the sale of these shares to Atlas Venture Life Science Advisors, LLC.
• Booth disclaims beneficial ownership except to the extent of his pecuniary interest.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard compensation practices. The grant aligns director interests with shareholders.

Positives

• The stock option grant aligns the director's interests with those of the shareholders.
• The vesting schedule encourages continued service on the board.

Industry Context

Stock option grants are a common form of compensation for directors, especially in the biotech industry, to align their interests with shareholders and incentivize long-term value creation.

Comparison to Industry Standards

• Director compensation packages, including stock options, vary widely across the biotechnology industry depending on company size, stage of development, and board responsibilities.
• Comparing Vigil Neuroscience's director compensation to peers like Denali Therapeutics or Biohaven Pharmaceuticals would provide a better understanding of its relative competitiveness.
• Stock option grants are a standard component of director compensation packages in the biotech industry, often vesting over a multi-year period to incentivize long-term commitment.

Stakeholder Impact

• The stock option grant could have a slightly positive impact on shareholders by aligning director incentives with long-term value creation.
• The grant has a positive impact on the director, Bruce Booth, by providing equity-based compensation.

Key Dates